Breakthrough pain: characteristics and impact in patients with cancer pain

Few surveys have been performed to define the characteristics and impact of breakthrough pain in the cancer population. In this cross-sectional survey of inpatients with cancer, patients responded to a structured interview (the Breakthrough Pain Questionnaire) designed to characterize breakthrough pain, and also completed measures of pain and mood (Memorial Pain Assessment Card (MPAC)), pain-related interference in function (Brief Pain Inventory (BPI)), depressed mood (Beck Depression Inventory (BDI)), and anxiety (Beck Anxiety Inventory (BAI)). Of 178 eligible patients, 164 (92.2%) met the criteria for controlled background pain. The median age was 50.6 years (range 26 to 77 years), 52% were men, and 80.6% were Caucasian. Tumor diagnoses were mixed, 75% had metastatic disease, 65% had pain caused directly by the neoplasm, and a majority had mixed nociceptive-neuropathic pain. The median Karnofsky Performance Status score was 60 (range 40 to 90). Eighty-four (51.2%) patients had experienced breakthrough pain during the previous day. The median number of episodes was six (range 1 to 60) and the median interval from onset to peak was 3 min (range 1 s to 30 min). Although almost two-thirds (61.7%) could identify precipitants (movement 20.4%; end-of-dose failure 13.2%), pain was unpredictable in a large majority (78.2%). Patients with breakthrough pain had more intense (P < 0.001) and more frequent (P < 0.01) background pain than patients without breakthrough pain. Breakthrough pain was also associated with greater pain-related functional impairment (difference in mean BPI. P < 0.001), worse mood (mood VAS, P < 0.05; BDI, P < 0.001), and more anxiety (BAI, P < 0.001). Multivariate analysis confirmed that breakthrough pain independently contributed to impaired functioning and psychological distress. These data confirm that cancer-related breakthrough pain is a prevalent and heterogeneous phenomenon. The presence of breakthrough pain is a marker of a generally more severe pain syndrome, and is associated with both pain-related functional impairment and psychological distress. The findings suggest the need for further studies of breakthrough pain and more effective therapeutic strategies.

[1]  R. Portenoy,et al.  Breakthrough pain: definition, prevalence and characteristics , 1990, Pain.

[2]  A. Banning,et al.  Treatment outcome in a multidisciplinary cancer pain clinic , 1991, Pain.

[3]  A. Beck,et al.  An inventory for measuring clinical anxiety: psychometric properties. , 1988, Journal of consulting and clinical psychology.

[4]  H. Thaler,et al.  Pain in ambulatory patients with lung or colon cancer. Prevalence, characteristics, and effect , 1992, Cancer.

[5]  J. Holland,et al.  The memorial pain assessment card. A valid instrument for the evaluation of cancer pain , 1987, Cancer.

[6]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[7]  C. Cleeland,et al.  Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases , 1983, Pain.

[8]  J. Yates,et al.  Evaluation of patients with advanced cancer using the karnofsky performance status , 1980, Cancer.

[9]  R. Portenoy,et al.  Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study , 1999, PAIN.

[10]  S. Mercadante,et al.  Predictive factors in advanced cancer pain treated only by analgesics , 1992, Pain.

[11]  E. Bruera,et al.  A prospective multicenter assessment of the Edmonton staging system for cancer pain. , 1995, Journal of pain and symptom management.

[12]  R. Portenoy Treatment of temporal variations in chronic cancer pain. , 1997, Seminars in oncology.

[13]  Katherine R. Edwards,et al.  When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function , 1995, Pain.